Lung cancer drug interaction study: how AZD9291 affects cholesterol medication

NCT ID NCT02197234

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 18 times

Summary

This study looked at how a lung cancer drug (AZD9291) affects the way the body processes simvastatin, a common cholesterol medicine. It involved 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC) whose disease had worsened after previous treatment. The goal was to measure drug levels in the blood to understand any interactions, not to test the cancer drug's effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Atlanta, Georgia, 30322, United States
Research Site

Leuven, 3000, Belgium
Research Site

Angers, 49055, France
Research Site

Dijon, 21079, France
Research Site

Marseille, 13385, France
Research Site

Rennes, 35033, France
Research Site

Saint-Herblain, 44805, France
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 08041, Spain
Research Site

Madrid, 28046, Spain
Research Site

Seville, 41013, Spain

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER